

MAP Pharmaceuticals, Inc.  
Form 8-K  
October 16, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 16, 2012

**MAP PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

|   |                                     |  |
|---|-------------------------------------|--|
| Delaware  | 001-33719                           | 20-0507047   |
| <b>(State or Other Jurisdiction<br/>of Incorporation)</b> | <b>(Commission<br/>File Number)</b> | <b>(IRS<br/>Employer<br/>Identification<br/>No.)</b> |
| 2400 Bayshore Parkway, Suite 200, Mountain<br>View, CA    |                                     | 94043  |
| <b>(Address of Principal Executive Offices)</b>           |                                     | <b>(Zip Code)</b>                                    |

Registrant's telephone number, including area code: (650) 386-3100

**(Former Name or Former Address, if Changed Since Last Report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

In a press release issued on October 16, 2012, MAP Pharmaceuticals, Inc. (the “Company”) announced that it has resubmitted a New Drug Application to the U.S. Food and Drug Administration for the Company’s LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d)Exhibits

Exhibit No. Description

99.1 Press Release of MAP Pharmaceuticals, Inc., dated October 16, 2012

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 16, 2012

MAP PHARMACEUTICALS, INC.

By: /s/ Charlene A. Friedman

Name: Charlene A. Friedman

Title: Senior Vice President, General Counsel and Secretary

**INDEX TO EXHIBITS FILED WITH**

**THE CURRENT REPORT ON FORM 8-K DATED OCTOBER 16, 2012**

Exhibit Description

99.1 Press Release of MAP Pharmaceuticals, Inc., dated October 16, 2012